Share Fund
To provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Scheme Class | Equity |
Scheme Category | Sector - Healthcare |
Expense Ratio | 0.92% |
Min subscription | ₹ 5,000 |
Scheme Type | Open-ended |
Scheme AUM (in Crs.) | ₹ 2,980 |
AMC AUM (in Crs.) | ₹ 2,83,807 |
Min Addition Subscription | ₹ 1,000 |
Benchmark Type | S&P BSE Healthcare PR |
Exit Load | Exit load of 0.5%, if redeemed between (0-15) days. No Exit load, if redeemed after 15 days. |
Fund | Min SIP Inv. | Min Inv. | Returns 3Y |
---|---|---|---|
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 23.35% |
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 23.35% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 20.13% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 20.32% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 20.13% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 20.32% |
Company | Holding Type | Asset(%) |
---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | 13 |
Divi's Laboratories Ltd | Equity | 7 |
Max Healthcare Institute Ltd Ordinary Shares | Equity | 7 |
Lonza Group Ltd ADR | Equity | 6 |
Cipla Ltd | Equity | 5 |
Aurobindo Pharma Ltd | Equity | 4 |
Lupin Ltd | Equity | 4 |
Aether Industries Ltd | Equity | 4 |
Jupiter Life Line Hospitals Ltd | Equity | 4 |
Gland Pharma Ltd | Equity | 4 |
Asset | Percent |
---|---|
Equity | 97 |
Cash - Repurchase Agreement | 2 |
Cash - Collateral | 0 |
Sector | Percent |
---|---|
Healthcare | 89 |
Basic Materials | 7 |
Cash - Repurchase Agreement | 2 |
Equity | 2 |
Cash - Collateral | 0 |
Fund Manager
Tanmaya Desai
13+ years of experience
Pradeep Kesavan
0+ years of experience
About
partnerforlife@sbimf.com
Phone
18002093333
Address
9th Floor, Crescenzo,,C-38 & 39, G Block, Bandra Kurla Complex,,Bandra (East), Mumbai, Mumbai - 400 051